Sana Pharma Medical Sustainability Report 2023

Content

1.	SANA PHARMA MEDICAL	3
2.	MARKET SITUATION	10
3.	PRODUCT PORTFOLIO	13
4.	SUSTAINABILITY	16
5.	CORPORATE GOVERNANCE	27
6.	GRI CONTENT INDEX	34
7.	APPENDIX	41

CO	NIT	E NI	тс
υU	INI		13

1.SANA PHARMA MEDICAL......32.MARKET SITUATION......103.PRODUCT PORTFOLIO......134.SUSTAINABILITY.....165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.....347.APPENDIX.....41

1. Sana Pharma Medical

Technical developments, huge changes in society the last decades together with a growing older population, have resulted in new demands, living habits and lifestyle diseases.

Sana Pharma medical has taken seriously the growing demand to provide knowledge and first line treatments with good safety profile.



CONTENTS

Sana Pharma Medical

Sana Pharma Medical is a Nordic pharmaceutical wholesaler with head quarter at Lysaker (Oslo) in Norway, and with offices in Sweden (Stockholm), Finland (Helsinki) and Denmark (Copenhagen). We have an extensive scalable in-house competence of all functions needed in a healthcare company. Our platform consists of quality assurance, regulatory affairs, pharmacovigilance, finance, third-party logistics (3PL), design and marketing competence. The majority of the staff work at the head office in Oslo, Norway, but several functions and Executive Managers are placed in the other countries. The organisation consists of the following departments:



Company info:

• Sana Pharma Medical AS 968671340 (Norway)

Our local subsidiaries are:

- Sana Pharma Medical AB 559062-5843 (Sweden)
- Sana Pharma Medical OY 2911469-3 (Finland)
- Sana Pharma Medical ApS 42433381 (Denmark)

The local subsidiaries are involved in marketing and sales as well as pharmacovigilance, quality and regulatory activities.

Localisations:

Norway, Head Quarter Lysaker, outside Oslo Philip Pedersens vei 20, 1366 Lysaker

Sweden, Stockholm, Svärdvägen 21, 182 33 Danderyd, Gothenburg Kungsgatan 9, 411 20 Göteborg

Finland, Helsinki Plaza Business Park Tuike, Äyritie 22, 01510 Vantaa

Denmark, Copenhagen C/O Caspian Coworking A/S Svanevej 22, 2400 København NV




1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	1(
3.PRODUCT PORTFOLIO	1
4.SUSTAINABILITY	16
5.CORPORATE GOVERNANC	E2
6.GRI CONTENT INDEX	3
7.APPENDIX	4


Sana Pharma Medical at a glance A valuable fast-growing Nordic pharmaceutical company

- Sana Pharma medical was established in 2014 and became part of Sagacia AS in 2023.
- Sana Pharma Medical, is a rapidly growing pharmaceutical company based on the commercialization of in-house developed products
- Full in-house scaled pharmaceutical platform to further EU expansion
- Sana Pharma Medical is a well-resourced platform with all key pharmaceutical functions, processes and systems in-house
- 2023 revenue of NOK 61m across 11 products and more products to be launched in 2024 and onwards
- Premium priced quality products, whereas 92% owned products
- Excellent price winning marketing and pharmacy partnership

Sana Pharma Medical has established itself as the Nordic's market leader within the Sleep & Anxiety categories



Shareholders and entities overview



1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.1
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.2
6.GRI CONTENT INDEX	3
7.APPENDIX	4

Sana Pharma Medical 2023

About Sana Pharma Medical

- Sana Pharma Medical is a pharmaceutical company with a strong commitment to improving health and wellbeing of people. Sana Pharma Medical was established in Norway and started operations in 2015. Expanded to Sweden in 2016, followed by Finland in 2018 and Denmark in 2021. We are EU GDP certified and wholesalers in Norway and Finland, selling OTC, medical devices and food supplements through pharmacies. Our purpose is to help people to a better life and to ensure quality first line products on the Nordic market.
- Sana Pharma Medical has extensive inhouse competences, and a well-resourced Nordic scalable pharmaceutical platform for further expansion. We are a fast-growing valuable company, owing more than 94% of our brands, which we are successfully marketing in cooperation with pharmacies towards healthcare professionals, in addition to end consumers.
- We strive to challenge the traditional pharmaceutical market in an innovative way, which has resulted in several pharmacy awards. In all our operations quality and ethics are important guidelines.



Our purpose is to improve health and increase quality of life

CEO summary



Effective from July 1, 2023, Sana Pharma Medical seamlessly merged with the Norwegian company, Sagacia, distinguished for its excellence in healthcare sector business development. Sagacia perfectly complements our dedication to organic growth strategy through providing new medical products on the Nordic market. This strategic approach not only ensures control and ownership of our assets but also lays the foundation for a sustainable business that benefits all stakeholders.

At present, Sana Pharma Medical hold the top 1 market share position within sleep and anxiety products across Nordic pharmacies. Our distinguished standing is underlined by a proven track record in shaping and developing this specific category, culminating in a nomination for the "Category Builder 2023" award in Apo1.

In 2023, we strategically broadened our category portfolio to include Pain and Circulation. The introduction of Glitinum in Norway, Sweden, and Finland marked a significant milestone as the only OTC migraine prevention product in the Nordics. Simultaneously, Senikol, a cholesterol depletion product, was launched in Norway and Sweden. In the coming years, our Nordic focus will be around Pain and Circulation, as well as our established category Sleep and Anxiety.

In 2023 we prepared for geographic expansion and are now wholesaler in Denmark after audits from national medical and food authorities. We are looking forward to providing our products to increase quality of life in the Danish market. The organization is prepared for sales channel expansions, and we will explore a variety of possibilities in 2024.

We take great pride in presenting our sustainability report, a reflection of our commitments to corporate governance, environmental responsibility, and social impact, as well as our commitment to improve health and quality of life for people.

1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.1(
3.PRODUCT PORTFOLIO	.1
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.2
6.GRI CONTENT INDEX	3
7.APPENDIX	.4

Increase quality of life

Provider of first line treatments


- Sana Pharma Medial is providing first line treatment with few side effects. This is a good starting point or alternative before treatment with medications having more severe side effects are initiated. Both end consumers and health care professionals are looking for effective and right first line treatment.
- We have a focus on right products for right problem, and with as few side effects as possible. By increasing knowledge of our products in the pharmacies, the support from HCP make sure the end consumer are giving the right treatment. We have first line treatment products within the Sleep & Anxiety, Menopause, circulation and Pain categories.

Increase categories portfolio

- In 2023, our focus category was Sleep & Anxiety, and we are the brand owner of all products in this category. Sleep & Anxiety has been our focus category for years, but in 2023 we launched products into two new focus categories.
- In 2023 we expanded our product portfolio with two products own by us. Senikol in the circulation category, and Glitinum in the new pain category. In2024, we are expanding the pain category with Giduxa.
- We will in the next coming years expand and invest more in all our categories in the Nordics.

Launching of new product

- In 2023, we continued building Solvenix in Sweden and Norway, an OTC medicine treating heavy, swollen and painful legs due to decreased blood flow (chronic venous insufficiency). We are the MA holder of Solvenix, which is an alternative or an add on to support stockings. This is the only OTC medicine in this category in both countries.
- We launched Senikol and Glitinum in Norway and Sweden in 2023 followed by Finland and Denmark in 2024.
- Giduxa, reducing joint pain, will be launched in all Nordic countries during 2024.



SANAPHARMA


1.SANA PHARMA MEDICAL......32.MARKET SITUATION........103.PRODUCT PORTFOLIO.......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.......347.APPENDIX......41

Extensive scalable in-house competences

Full suite of development and commercialization capabilities

Capabilities	Description				
Wholesaler	 In-house Responsible Person/pharmacist (FFA) in Norway, Finland, Sweden GDP certificates, WDA in NO and FI (DK/FI 2023) 				
In-house QA/RA	 Working in close relation to authorities Regulatory maintenance of our products Internal check of marketing compliance with all laws and legislations Apply for MAS 				
In-house PV	 Apply for MAs Inhouse Pharmacovigilance (PV) setup In-house QPPV Responsible Persons 				
In-house marketing production	 Towards consumers/HCP/Pharmacies Multichannel OTC/Rx marketing Extensive TV and Digital Communication Internal SoMe communication and analysis 				
Quality & Management	 Internal build-up of the Quality- and ESG System Internal SOPs and Policies for quality assurance and quality risk management 				

Which are leveraged in a structured product development process



- Focus is opportunities where we can make a sustainable health impact on the quality of life for the user and in line with the consumer/market insights
- We create subcategories to already established categories together with pharmacies
- Quality, efficacy and claim support on all products are central

We are proud of our track-record identifying market opportunities and commercializing products across the product life cycle



1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	10
3.PRODUCT PORTFOLIO	13
4.SUSTAINABILITY	16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	.3
7.APPENDIX	.41

CONTENTS

Strong cross-country Executive Management Team

Executive Management Team with outstanding competences, experiences and passion for business

Heidi Tveit

CEO Norway

- Founder of Sana Pharma Medical in 2014
- Substantial experience from business development and operations
- 25+ years within medical research, at University of Oslo, Norway as an Associate Professor
- Board member of medicine developing companies, GAT Biosciences, AdvanSyn Bio SL, GAT Therapeutics, ALGAKTIV, Greenaltech, Leanbio

Anna Bentinger Elmblad





- Experienced leader with passion for brand, portfolio, and team transformations within pharma-and healthcare
- Enjoys of the entire commercial spectrum, from strategic planning to execution
- Track record of driving commercial success in companies such as Karo Pharma, Trimb, TEVA, Allergan and more

Our executive management team (EMT) is a cross-functional, multinational and agile team of experts within different fields, with vast experience from the pharmaceutical industry.

This high level of competence and experience forms a EMT with optimal capability to ensure that we perform according to our strategy in all countries.

Morten Brennesvik-Jensen

CFO Norway

- 25+ years within finance and M&A and 20+ in pharma
- Previously CEO at Nordic Health
- Previously experience with Nycomed Pharma, Takeda, Orkla etc. in CFO/BD roles

Rashid Bhatti

Supply Chain & Logistics Norway

- 14+ years' experience with organizational SC & Logistics strategy
- Extended expertise across various industries covering B2B, B2C sales
- Successfully held both operational and managerial roles, demonstrating versatility across multiple projects
- Experience with diverse organizations, (Demand Planning, Forecasting & Replenishment) at Nille AS, Head of Logistics at Mercante Grossist

Carolina Vilenius

QA RA PV Finland

- Responsible Pharmacist (FI), EU-QPPV
- 7+ years' experience working with quality assurance
- Experience having worked within a pharma wholesaler (with large focus on regulatory matters)
- M.Sc. In Pharmacology



1.SANA PHARMA MEDICAL......32.MARKET SITUATION.......103.PRODUCT PORTFOLIO......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX......347.APPENDIX......41

2. Market Situation

Technical developments, huge changes in society the last decades together with a growing older population, have resulted in new demands, living habits and lifestyle diseases.

Sana Pharma medical has taken seriously the growing demand to provide knowledge and first line treatments with good safety profile.





1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	.34
7.APPENDIX	.41

Several trends are driving demand of new OTC products

With our mission to **improve health and increase quality of life.** We have identified areas were there are gaps in the market, where we belief consumers can start their treatment journey **by self-medication with trusted, effective and a good safety profile** for the body. Most of our portfolio is, as a result of this, based on herbal medicines to increase health awareness. We have a clear target related to secure proper health information and work intensively with educations and easy access of information and guidance. We are also focusing on offering products in an easy way so that more **people can improve health and increase quality of life** due to availability of self-medication.

Increased health awareness

Health information availability

Self medication without adverse events





Accelerated by the pandemic, a focus on wellbeing and staying healthy has been key to a much larger group of people than before. This trend has led to an increase in demand for OTC products promoting wellness, such as vitamins, supplements, and herbal remedies.

This together with today's demographic development with a larger group of elderly consumers there is **an increased need for easy access products and support with everyday needs**.

We work with the objective **to prevent the bigger problems by solving needs early** for the consumers. Our full portfolio of **products is offered to consumers without prescription**. Our hero products with documented effect are OTC medicines or food supplements with EFSA claims.

Consumers today often start their treatment

journeys online. This easy access to information has empowered consumers to make more informed decisions about their healthcare. This trend has led to an increase in demand for products that are backed by clinical studies and with a proven track record of success.

We have **specific product information targeting HCPs** and an in-house medical advisor.



There is an increasing interest towards sustainability and a closeness to nature. We notice a spill over effect from that macro trend in terms of an increased **interest towards herbal based medicines** that have a low risk of adverse events.

Consumers are also seeking out easy to use products without prescription requirements. Products they can try out as a first line treatment or supplement to already established treatments that has a kind profile related to possible adverse events.



1.SANA PHARMA MEDICAL......32.MARKET SITUATION.......103.PRODUCT PORTFOLIO.....134.SUSTAINABILITY.....165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.....347.APPENDIX.....41

A strong position within the fast-growing Sleep & Anxiety category

The sleep & anxiety category is one of the **fastest growing OTC categories within pharmacies**. On a European level >40% of the population have problems. Local surveys point at 30% of the population- however that is without taking the people with anxiety fully into the calculation.

Today only 15% of the population with identified issues are buying products to ease their problems. Therefore, there is a large group from where we can recruit and offer a difference to the quality of life by offering safe and effective products.

In 2023, Sana Pharma Medical has 1/3 of the sleep and anxiety products in the Nordic pharmacy market.

Norway	Sweden	Finland
 Sana Pharma Medical is the preferred partner for pharmacies. We are driving the category and are invited yearly to educate pharmacy personnel. With our four brands we currently hold a market share of 66%* and have been successful by offering a range of products to support with the right type of problems (and active ingredients) towards the right type of problem and with a clear differentiation within the range. Our products help consumers with daytime anxiety, falling asleep and having a good qualitative sleep throw-out the night. 	 With our two brands we currently hold a market share of 26% * and offering products to support with the right type of products (and active ingredients) towards the right type of problem. Our products help consumers with both daytime anxiety and having a good qualitative sleep throwout the night. The Swedish market is a young market where the category still has a lot of potential in terms of additional products. 	 With our three brands we currently hold a market share of 6%* and are offering products to support right type of problems (and active ingredients) towards the right type of problem. Our products help consumers with both daytime anxiety and having a good qualitative sleep throwout the night. The Finnish market is a mature sleep and anxiety market where our products has high competition mainly from melatonin products.

1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	34
7.APPENDIX	.41

3. Product Portfolio

New lifestyle diseases and increased medical knowledge through digital information, have resulted in a demand to get first line treatment with limited side effects. Sana Pharma Medical provide effective quality OTC products with a good safe profile.


Our Product portfolio is supported by the health care professionals in the pharmacies.




1.SANA PHARMA MEDICAL......32.MARKET SITUATION.......103.PRODUCT PORTFOLIO.......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.......347.APPENDIX......41

Track record of category expansion and launch excellences

- Together with customers (pharmacies), Sana Pharma Medical has built up a fast-growing Sleep & Anxiety category. Sana Pharma Medical is reaching > 65% MS, MAT* in Norway.
- A solid professional communication strategy targeting HCP, Pharmacies and end consumer at the right point in time has made it possible to reach the above levels with smart investments and still an attractive brand contribution
- #1, #2 and #4 MS* position in the Sleep & Anxiety OTC market
- Several awards for excellent pharmacy launching





• * MAT Iqvia Oct 2022, MAT= moving annual total

 $\underline{1.\ https://www.folkhalsomyndigheten.se/livsvillkor-levnadsvanor/psykisk-halsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa/balsa-och-suicidprevention/statistik-psykisk-halsa-och-suicidprevention/statistik-psykisk-suicidprevention/statistik-psykisk-halsa-och-suicidprevention/stati$



1.SANA PHARMA MEDICAL......32.MARKET SITUATION......103.PRODUCT PORTFOLIO.......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX......347.APPENDIX......41

() SANAPHARMA

Product portfolio- excellent first line treatments

			Key products c	verview	Owned trademark (EU&NO)	Classification	Ownership
	Sedix		Anxiety •	Traditional herbal drug used to ease anxiety / fall asleep	\checkmark	ОТС	Eternal
-	Lunixen		Sleep Disturbance	Traditional herbal sleep sedative improving sleep quality and length	\checkmark	ОТС	Eternal
Sleep & Anxiety	Melatonin (Several SKUs)	Alter Alter	Falling ■ Asleep	Pills & spray used to regulate the circadian rhythm (1 mg Melatonin), for falling asleep	\checkmark	FS	Eternəl
	Duranoct		Falling Asleep∕	Combination product used to regulate the circadian rhythm (1.9 mg Melatonin) for falling asleep	\checkmark	FS	Eternal
Circulation/	Solvenix		Swollen & heavy legs	Well establ herbal medicine, reduce symptoms and discomfort, used as an alternative or in addition to compression stockings	\checkmark	отс	MAH and Brand owner 2 MA (SE/NO) (2 MA (FI/DK)2024)
Cardio	Senikol		Reduce Cholesterol	Caps taken with food, to lower cholesterol level 8-12%	\checkmark	FS	Product and Brand owner eternal
Pain	Glitinum	AT STATE	Prevent migraine	Traditional herbal medicine preventing migraine	\checkmark	отс	MAH and Brand owner (SE/NO/FI/DK)
	Remisoft		Intimate Care	Hormone-free vaginal cream for treatment of vaginal discomforts		MD class IIa	License automatically
Women's health	Remifemin	remifemin	 Menopause 	Herbal medicine for treatment of menopausal symptoms		отс	renewed every year

In 2023:

- The product portfolio consisted of 11 products, including overthe-counter (OTC) branded medicines, food supplements and medical devices. Most of our current products are based on herbal substances and are mainly sold through pharmacies.
- The pain category was opened by launching Glitinum, a migraine prevention OTC herbal medicine. The nest pain product will be launched in 2024, Giduxa, reducing joint pain.
- The circulation/cardio category was expanded by launching Senikol, a cholesterol depletion product.

CONTENTS

4. Sustainability

Sana Pharma Medical provide high-quality products and treatments for several diseases and conditions. We manage our activities and products using a sustainable strategy, focusing on quality, being an attractive employer, profitable growth and taking environmentaland social responsibility. Most of the products are herbal based OTC with kind safety profiles.

The Sana Pharma Medical sustainability report was prepared in accordance with the GRI Standards, and the GRI content Index is found on page 33





1.SANA PHARMA MEDICAL......32.MARKET SITUATION......103.PRODUCT PORTFOLIO......134.SUSTAINABILITY.....165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.....347.APPENDIX.....41

Improve health & increase quality of life in a sustainable way

Sana Pharma Medical's mission is to provide products to to improve health & Increase quality of life through treatment with quality OTC self medications, well tolerated with a kind safety profile. We focus on the big lifestyle diseases, and thereby increase sustainable health impact for end consumers and the society. Through focusing on our objectives, we strive to meet customers, employees and all stakeholders' expectations when it comes to sustainable business operations

Customers- Availability of Quality Products & Operations


Sana Pharma Medical focus on quality in all our operations and products. We monitor and measure our services towards customers, and the quality of products for end consumers. Product safety is monitored and followed up by our pharmacovigilance System further followed up by the European Medical Authorities (EMA). We have GMP certified suppliers, and GDP certified customers. Our customers monitor our quality work, and together we set goals for quality work.

Employees – Attractive employer

We believe our employees are the cornerstone of our success. We are dependent on qualified, competent and happy employees. We care about the well being of our employees, and are focusing on balancing work and private life, facilitate actions towards mental and physical health and are facilitating good working environment. We measure employee satisfaction and engagement yearly to ensure we create an attractive workplace inspiring our team. We are yearly working on the development programs for each employees.

All stakeholders – Sustainable growth

Sana Pharma Medical is a fast-growing company, with a focus on sustainable growth. We continue to strengthen our position in our current categories and are expanding our portfolio categories and geographically in the Nordics. To have a sustainable growth we focus on high quality products and operations in all aspects and have a profitable growth with clear financial goals.





1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
5.GRI CONTENT INDEX	34
7.APPENDIX	.41

Objectives

Increase availability of OTCs

Sustainable growth

Quality Products & Operations

Attractive employer

Sana Pharma Medical aims to enhance people's health and increase quality of life. This by increasing availability of first line self-medication products towards lifestyle diseases and other health conditions, with limited or few effects. Our high-quality products across various categories prevent and treats illnesses and improve the general health in the population. We aspire to ensure the availability of our products wherever customers choose, aiming to meet their needs seamlessly.

Sana Pharma Medical is a fastgrowing pharmaceutical company, with focus on organic growth of own medical products. We are committed to sustainable growth, launching our high-quality products in a sustainable manner in market after market. By strengthening our position in selected categories, we create value for all stakeholders in a sustainable way. Our corporate governance ensures a healthy financial and operational business, closely monitored and supported by our category and geoexpansion strategy. Join us as we work towards a healthier and more sustainable future.

At Sana Pharma Medical, quality is at the heart of everything we do. We continually monitor the quality of our products through feedback on adverse events and effectiveness. Our focus is on finding high-quality products with minimal side effects that can be used as a first-line self-medication treatment. We prioritize providing the "right products for the right condition" to end consumers, healthcare providers, and pharmacies. Our commitment to quality extends to our customers, and we closely monitor our operations, implementing appropriate mitigations when necessary.

At Sana Pharma Medical, we believe that our employees are the cornerstone of our success. We care deeply about their health and well-being, and we strive to provide excellent working conditions to minimize sick days. We believe that happy employees lead to better business outcomes, and we measure employee satisfaction and engagement yearly to ensure that we are doing all we can to support them.

We work hard to create an attractive workplace that inspires and challenges our team. Our innovative and inspiring company culture, combined with our investment in employee wellbeing, creates a platform for success.

Sana Pharma Medical focus on:

- having product in several categories
- availability in several sale channels

Sana Pharma Medical focus on:

- good corporate governance
- ambitious but realistic financial goals

Sana Pharma Medical have:

- quality 1-line self -medication products
- customer operation index > 97*

Sana Pharma Medical focus on:

- mental and physical employee health
- engaged and loyal employees

CONTENTS	4. SUSTAINABIL	ITY		SANA PHARMA ME	DICAL SUSTAINABILITY REPORT 2023
 1.SANA PHARMA MEDICAL3 2.MARKET SITUATION10 3.PRODUCT PORTFOLIO13 4.SUSTAINABILITY16 5.CORPORATE GOVERNANCE27 6.GRI CONTENT INDEX34 7.APPENDIX41 	Objectives	Increase availability of OTCs	Sustainable growth	Quality Products & Operations	Attractive employer
	Targets Goals	Launch new products To monitor how we are increasing availability of OTC, we are measuring the availability of different products (SKUs) in different markets. Goals 2024: total 7 launches in 4 markets	Revenue growth Increased product launches, geo expansion and sales channels expansion, the company is increasing the revenue while building up new categories Goals 2024: Revenue growth of 90% vs LY	Safe product use To secure safe products use, we have quality products and good communication to all customers. Safe product use is therefore measure reported adverse event/sold SKUs Goals 2024: < 1‰ deviation/SKUs sold	Satisfied and engaged employees Employees satisfaction is important for us, and we are measuring the satisfaction and engagement by performing yearly survey. We are measuring employee satisfaction trough external survey score (1-5)
		Outcome 2024: Geo Expansion (DK) Build up B2B business in DK. Goals 2024: 3 products on the market Outcome 2024: Sales channels expansion By increasing the sales channels, we are giving customers the possibility to choose how and where to get the OTC.	Outcome 2024: Increase product portfolio categories Sleep and Anxiety was 87% of revenue LY. To have a more sustainable business, new product categories are launches, and most of the revenue growth will come from these category Goals 2024: 88% growth - new categories Outcome 2024:	Outcome 2024: Quality operations Low scrapping: When performing quality activities, we secure little or no scrapping of products. We are measuring scrapping value in relation to COGs Goals 2024: <4% scrapping vs COGs Outcome 2024: Customer satisfaction: Quality system management provide satisfied customers. We measure customer satisfaction through	Goals 2024: improve satisfaction score Outcome 2024: Healthy employees We care about our employees and their health. We strive towards excellent working conditions and to minimize sick days as a result of working conditions. We are measuring number of reported sick days (work related)
		B2B MM expansion: Open up for sale through Mass Market (MM) Goals 2024: MM launch in NO/SE/FI Outcome 2024: D2C Products & Geo expansion: D2C business in SE and NO and will expand D2C offerings in those markets while introducing D2C in FI/DK Goals 2024: 6 D2C products in NO & 3 in SE	Launch 1 new product in all countries Cholesterol depletion and pain products will be available in most pharmacies in SE and NO in Feb 2024, and in DK and FI during 2024. Expansion of the pain category will secure a sustainable growth pilar for the company	 % fullfillment of orders/delivery to B2B and D2C Goals 2024: 95% satisfaction Outcome 2024: Forecast accuracy we are monitoring and following product forecast Goals 2024: 70% accuracy 	Target 2023: 0 sick days FTE/Y Outcome 2024: 0 Gender equality We have a focus on equality and will secure a gender diversified EMT group. • Gender split in EMT
SANAPHARMA MEDICAL		Goals 2024: 6 D2C products in NO & 3 in SE Outcome 2024: Goals 2024: 4 D2C launch in FI & 3 in DK Outcome 2024:	Goals 2024: Giduxa launch in 4 countries Outcome 2024:	Outcome 2024:	Goals 2024: ≥50% females in EMT Outcome 2024: 1

1.SANA PHARMA MEDICAL......32.MARKET SITUATION.......103.PRODUCT PORTFOLIO.......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX......347.APPENDIX......41

Improve health & increase quality of life in a sustainable way

Sana Pharma Medical's UN focus areas

Focus 2023

- Healthy Employees
- Safe Product Use

- Next 5Y
- Reduce Emissions
- Sustainable use of Resources

Ongoing Commitments

- Responsible Operations
- Gender Diversity









1.SANA PHARMA MEDICAL......32.MARKET SITUATION......103.PRODUCT PORTFOLIO......134.SUSTAINABILITY.....165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.....347.APPENDIX.....41

Stakeholders

Sana Pharma Medicals sustainability strategy make sure we are operating and having a close dialog with our stakeholders to make sure we are integrating the most material area into our strategy. We are monitoring the most important areas for out stakeholders by frequently performing an external and internal materiality analysis. Executing good corporate governance and having a clear code of conduct provide us with a group corporate culture benefiting all stakeholders.

Customers

Our customers are healthcare professionals (HCPs), pharmacies, and end users. We provide relevant Information and solutions for all our customers through multichannel marketing, educations related to our products and categories, and we encourage end consumers to get competent guidance in pharmacies and on our web pages.

	нср	Pharmacies	End user
Communication	Alternative 1-line treatment products	Right products to right symptoms	1-line treatment without sever side effect
Solution	Provide an alternative without sever side effects and/or addictions	Clear and simplified information to remember	Increased quality of life



Employees

Our employees are our most important asset, and we feel a strong responsibility to be an attractive employer supporting their well-being and development. We encourage our employees in all functions and levels to produce ideas and thoughts to improve and make a difference in people's life. Besides offering fair wages and equal opportunities for employment, development and advancement we offer a good work-life balance and a safe working environment. We are committed to follow or overdue the general content of collective bargaining agreements. Employees are promptly informed about changes to their entity, and Sana Pharma Medical comply with all national laws in every country we are present. We track employee engagement and satisfaction on a regular basis and follow up on areas to improve.

Society

Given our involvement with pharmaceutical and medical products, we bear a significant responsibility to society concerning product and user safety, fostering optimal working conditions, minimizing environmental impact, and ensuring efficient use of resources and materials

New employes 2023: 4, FTEs Employee turnover 2023: 14% Financial contribution for exercise: 5 TNOK Work related illness: 0

We strive to attract high integrity employees who want to make a difference in people's lives, regardless of political, religious or cultural background.



1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	34
7.APPENDIX	.41

SANAPHA

Stakeholders

Suppliers

Our suppliers are located within the EU, and together with EU medical authorities we are regularly auditing and working together with the suppliers to secure safe and good operations and products. We try to use local suppliers, when possible, and in 2023 we spent 72% on local suppliers to support local industry. We purchase finished products directly from our suppliers, who have several types of products within their production facilities. We regularly follow up the suppliers on their compliance with our supplier code of conduct, and together we make sure our activities are compliant with our sustainability work. We are member of the Pharmaceutical Supply Chain Initiative (PSCI), due to our follow-up on supplier compliance with our Supplier and Partner Code of Conduct. PSCI membership is an important step in our aim to contribute to minimising the negative environmental impact from the pharmaceutical industry through good solutions for people, animals and the environment, with sustainable results.

All suppliers are working towards our sustainable code of conduct, and have all required certifications



Owners

We have a responsibility towards our owners, making sure our business provide a reasonable profit. By investing in Sana Pharma Medical the shareholders are investing in a profitable fast-growing pharmaceutical business working actively with environmental, social/human capital, and governance (ESG) issues.

Authorities

The competent EMT secure through all their operations, recourses, Quality Management System and reporting, compliance with all laws and legislations.

Materiality analysis

The executive management team has earlier performed a materiality analysis with internal and external stakeholders, to get their view on the most important topics for Sana Pharma Medical to focus on. We then pinpointed the areas where we have the best possibility to improve our sustainability performance, both in short and long term. The following areas were reported to be the most important ones, and have now been part of our focus areas to follow up on.

Interna stakeholders:

- Occupational health and safety.
- Workplace diversity and inclusion
- Increased "Quality of Life" for end consumers

External stakeholders:

- Supplier evaluation criteria's and fulfillment of SPM's CoC
- Handling of corruption and bribery
- High-risk-ingredients due to e,g, deforestation

1.SANA PHARMA MEDICAL......32.MARKET SITUATION.......103.PRODUCT PORTFOLIO.......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX.......347.APPENDIX......41

CONTENTS

Sustainability report 2023

Our yearly sustainability report contains information on how we currently address sustainability issues and presents our ambitions for the future. The CEO is responsible for compliance with laws, legislation, policies and procedure. We always aim to provide effective quality products with a good safety profile for end users, as well as for the environment. Standards are established to ensure the safety for our employees, customers and users. This can be seen within all steps in the value chain, production, transport, activities, customer towards our employees and end users. We support and respect internationally recognized human rights, such as the UN guiding principles on business and human rights, regardless of where we work. We have a zero-tolerance approach when it comes to bribery and corruption, which is also clearly reflected in our code of conduct and corporate policies.

Environmental sustainability

Sana Pharma Medical's environmental works is compliant with our Climate and Environmental Policy. The environmental effort is the principles of precaution and substitution. We continuously work resource-efficiently, minimizing environmental footprints. It is mandatory for all employees to have training on all company environmental related policies. Sana Pharma Medical's environmental impact is mainly through the waste and transport management. Financial risks are discovered when performing environmental policy risk assessments.

Waste management

Waste has generally a large impact on the environmental footprint. Therefore, waste management and recycling are natural activities in all our offices and activities. Furthermore, to decrease plastic waste, we stopped delivering products in plastic bundles during 2020. We have a focus on sustainable use of recourses, and strive to keep scraping of products <4% of COGs

Environmental sustainability related Policies:

- Climate and Environmental Policy
- Travel Policy
- Supplier and Partner Code of Conduct
- Sustainability Reports



Previously approved sustainability reports: https://www.sanapharma.se/hallbarhet The report was investigated by RSM Norge AS : <u>https://www.rsm.global/norway/nb/om-rsm-norge in 2022</u>, and the same set-up with information for the next year added in

1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	34
7.APPENDIX	.41

OK Contration Neldig brat Contration



Environmental sustainability

Sana Pharma Medical's environmental focus in 2023 has been to identify and monitor the company's emission footprint in accordance with Sana Pharma Medical's and the general Scope definition. We are currently reporting on Scope 3 emissions, specifically those related to employee business travel, transportation, and product distribution. While we are not currently reporting on Scope 1 and 2 emissions, we are committed to including Scope 2 in our reporting within the next five years. As we do not own any manufacturing sites and have limited involvement as a customer for such sites, measuring Scope 1 emissions is not feasible at this stage. However, as circumstances change, we will implement measurements for Scope 1 emissions.

Sana Pharma Medical`s Scope definitions: Scope -1 Emissions from direct sources

On-site manufacturing or industrial processes Owned facilities On-site transportation or company vehicles


Scope -2 Emissions form energy/utilities Purchased electricity, heating, cooling, and building

Scope-3 Indirect emissions from Supply Chain & Services Employee commuting or business travel Purchased goods and services Transportation and distribution of products

CO₂ Emissions Scope 3


CO₂ Emissions Business traveling

We make necessary efforts to limit travel and embrace digital collaboration. Covid-19 disruption led to reduced our travel in last couple of years and CO₂ emission rose by indispensable travel in 2023. However, when travel was necessary, we offset emissions and prioritized sustainable transportation. Moving forward, we're committed to further reducing emissions and enhancing sustainability measures.



CO₂ Emissions Transportation and distribution of products

Sustainability and environmentally friendly norms in overall SPM's supply chain and distribution channel. Foster green initiatives within supply chain management to enhance the company's reputation and overall business performed.



CONTENTS

Environmental sustainability

Environmental investments

Sana Pharma Medical strive to decrease environmental and its CO₂ footprint in several ways. We are measuring our CO₂ footprint and are compensating for our emission. We have established Sana Pharma foundation, investing in environmental projects lowering CO₂, as well as projects employees are passionate about. 200 NOK/FTE/month is transferred to Sana Pharma foundation and all employees together are deciding what environmental and/or social projects to investment in.

Sana Pharma Medical`s environmental investments

- Investing 200 NOK/FTE/mnd in our Sana Pharma foundation
- CO₂ compensation for all product and business transportations

Sana Pharma foundation

Sana Pharma foundation is a fund where investments are allocated to employee selected projects to support sustainability.

The imitative is driven fully by a steering group of employees who identify several project for the organization to learn more about and then vote for. The company is investing both environmental and social projects

Sana Pharma foundation focus areas in 2023:

Environmental focus: CO2 compensation (25,14 tons) for business travel and transport of products.

Social focus:

Mental health by supporting Fonden for Psykisk Hälsa.

$\rm CO_2$ compensation

Sana Pharma foundation chose to CO₂ compensate our business ravel and product transport with Gold Standard and Fairtrade-certificated projects.

- A project to provide water treatment systems to economically disadvantaged households and schools in Uganda. This initiative contributes to climate benefits by reducing the consumption of wood and coal for water boiling purposes.
- 2. A project in Tanzania dedicated to the conservation of forests through a remarkable collaboration with the Hadza tribe, a community of hunter-gatherers, and the Datoga tribe, a pastoralist community.





1.SANA PHARMA MEDICAL......32.MARKET SITUATION......103.PRODUCT PORTFOLIO.......134.SUSTAINABILITY......165.CORPORATE GOVERNANCE..276.GRI CONTENT INDEX......347.APPENDIX.....41

SANAPHA

Social sustainability

Our purpose is to provide products to improve health and increase quality of life, and we are identifying and managing business impact on people around us; employees, customers, partners, workers in the supply chains and the community. We are compliant with our policies and are frequently performing risks assessment and appropriate mitigations when needed.

Commitments to Customers and Partners

- We treat customers and Partners fairly
- We have zero tolerance for bribery or other forms of corruption, fraud or any other prohibited or unethical business practices.
- Our employees shall not offer, give, get or accept a gift, meal or entertainment if this could influence business judgement.
- We require a comply with laws and a minimum code of conduct from Suppliers and Partners.

- **Commitments to Communities**
- We have zero tolerance for bribery or other forms of corruption, fraud or any other prohibited or un-ethical business practices.
- We compete fairly, maintain decent business standards in advertising, sales, and competition.
- We are committed to and are following Human Rights in all operations.



Commitments to Employees

- We embrace diversity and inclusion in our working environment.
- We have a safe working place following our Occupational Health & Safety Policy, and all have an employee handbook describing culture, compensation and benefits.

Social sustainability related Policies:

- Suppliers and Third Parties CoC (Policy)
- Diversity & Inclusion Policy
- Employee Relation & Satisfaction Policy
- Occupational Health & Safety Policy
- Employee & Customer Privacy Policy (GDPR)

Investment in mental health

Sana Pharma Medicals employees have chosen to have an extra focus on preventing mental health. Through Sana Pharma foundation, we have invested in Fonden för Psykisk Hälsa.






1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	34
7.APPENDIX	.41

5. Corporate Governance

The objective of Sana Pharma Medical's corporate governance is to secure effective control of system and processes to secure accountability, transparency and responsibility towards shareholders interest in a profitable and sustainable way.






1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	34
7.APPENDIX	.41

Building confidence through Corporate Governance

Accountability	Transparency	Fairness	Responsibility						
Sana Pharma Medical are able to explain every operations performed and thereby build confidence amongst shareholders. We have a risk management system enabling us to understand, measure and perform mitigations to crucial risks for the building and future success of the business.	Transparency is crucial for building confidence, making sure we have nothing to hide in our way of performing operations. We provide both shareholders and stakeholders with clear information regarding our performance. This secure good and powerful decisions promptly.	We treat all shareholders within the share class equally. Fairness and ethics are main drivers through all our dealings and operations, securing support and high interest amongst investors.	We are executing our business in a responsible way by being accountable, transparent and fair. Responsibility means not taking unnecessary risks, act ethically and secure shareholder's interests. Responsibility is reflected in all actions and operations.						

Commitments to Integrity

- We follow all applicable laws in all our business operations wherever we are located.
- Compliance and ethics are important factors to create an ethical work environment.
- All managers and directors are supporting and following up all our policies, CoC and Business integrity.
- We shall not in any circumstances engage in any form of un-ethical business practice i.e any form of bribery (incl gifts, travels, or other benefits), corruption including extortion, embezzlement and fraud, or any other prohibited or un-ethical business practices.
- We are committed to highest stands of ethical conducts.
- We have frequently trainings and are constantly improving the policies and CoC.
- We strive to take ethical right decisions in challenging situations.
- We protect employees, suppliers, customers and others Personal Privacy.





1.SANA PHARMA MEDICAL	
2.MARKET SITUATION	1
3.PRODUCT PORTFOLIO	1
4.SUSTAINABILITY	1
5.CORPORATE GOVERNANCE	2
6.GRI CONTENT INDEX	3
7.APPENDIX	4

Corporate Governance

Sana Pharma Medical's corporate governance secure an effective way of managing and develop our resources in a profitable and sustainable way for our shareholders. Corporate governances involve stakeholders such as the board of directors (BoD), executive management team (EMT) and other shareholders. EMT is responsible for strategic planning, risk management and financial reporting to the BoD. BoD is approving total corporate strategy, and thereby secure shareholders interests. The objectives in Sana Pharma Medicals corporate governance is to be accountable to shareholders, transparent in operations, fair in dealing, and responsible in all actions.

Board of Directors (BoD)

- The BoD is elected by the shareholders (general assembly) and is appointing the CEO who is managing the economy, environment, and people.
- BoD approves corporate strategy suggested and presented by CEO.
- The corporate strategy is to build sustainable longterm values for shareholders.
- BoD is responsible for company performance.
- Chairman of the Board, Andres Kongsgaard Flaaten, is the highest responsible person of critical concerns.
- BoD approve the sustainability work and report.

Corporate Governance related Policies:

- Authorization instructions
- Sana Pharma Medical Code of Conduct
- Data protection & information Security Policy
- Business Integrity Policy (KOL/Partners)
- Business Continuity and Disaster Recovery Plan
- Product Approval and QA Information Policy
- Whistleblower & Complaint Policy

Executive Management Team (EMT)

- Sana Pharma Medical has a strong and competent EMT, developing and implementing corporate strategy.
- EMT is securing an effective short- and long-term executing of the company strategy.
- EMT is responsible for strategic planning, risk management and financial reporting.
- EMT report financial statement that fairly present the company financial situation.
- EMT report audits, risks and mitigations, and report compliant system and follow-ups.
- EMT produce yearly a sustainability report

Shareholders

- The total numbers of different shares are 184.931.567.
- 12 different entities are owners of the shares.
- The shareholders are appointing BoDs and auditors, to secure their interest and appropriate governance structure in place.






Essential in all SPMs` relationships are agreements, Code of Conducts, applicable laws and legislations

1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	27
6.GRI CONTENT INDEX	34
7.APPENDIX	41

Corporate Governance

Sana Pharma Medical's corporate governance secure commitment and compliance to all laws, legislations, policies, procedures, internal guidance.



CONTENTS

Management of Policies, CoCs and Plans

Sana Pharma Medical has built up a Total Management System, used for all operations in all countries. All policies, CoCs and plans including quality work are using the same Total Management System. All national laws and regulations are taken into account in the Management System and policies.

All policies and CoC are frequently trained according to the Training Management, and regularly risk assessments followed up by mitigations are performed.

Yearly, a management review meeting is performed, and the outcome of the total business is presented to the BoD prior to updating the sustainability report.

Trainings:

- Frequently : SOPs, Products, Policies and CoC
- Yearly training: GDP, PV

Sana Pharma Medicals identified risk categories:

- Product safety risks
- Operational risks
- Compliance risks
- Financial risks
- Policy risks

Total Management System:

- Risk Management
- Deviation Management
- Change Control Management
- Document Management
- self inspection
- Management review
- Training Management
- Communication Policy

Policies, Code of Conducts and Plans

Environmental

- Climate and environmental Policy
- Travel Policy
- Sustainability report

Social

- Diversity & Inclusion Policy
- Employee relation & Satisfaction Policy
- Occupational Health & Safety Policy
- Employee & Customer Privacy Policy (GDPR)
- Employee Handbook
- Suppliers and Third Parties CoC (Policy)

Governance

- Business Integrity Policy (KOL/Partners)
- Whistleblower & Complaint Policy
- Sana Pharma Medical CoC
- Business Continuity and Disaster Recovery Plan
- Data protection & information Security

Products


- Quality & Product Safety Policy
- Qualification and Approval of Suppliers and Products Policy

Raison consulting helped out with policies building Raison consulting: https://www.raison-consulting.com/



1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	1(
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	16
5.CORPORATE GOVERNANCE.	.2
6.GRI CONTENT INDEX	.3
7.APPENDIX	.4

Identifying, mitigate and reporting materiality topics



0 recalls, Mock recall performed in NO, SE, Fi & DK

#: amount

1.SANA PHARMA MEDICAL	3
2.MARKET SITUATION	.10
3.PRODUCT PORTFOLIO	.13
4.SUSTAINABILITY	.16
5.CORPORATE GOVERNANCE.	.27
6.GRI CONTENT INDEX	34
7.APPENDIX	.41

6. GRI Index

Sana Pharma Medical use the Global Reporting Initiative (GRI) standard content index as a guiding for our sustainability reporting to secure traceability and increase credibility and transparency.



Global Reporting Initiative



CONTENTS	6. GRI INDEX																				SA	NA Pł	HARM	1A MI	EDICA	L SU	STAIN	IABIL	ITY R	EPO	RT 202	23
1.SANA PHARMA MEDICAL32.MARKET SITUATION103.PRODUCT PORTFOLIO134.SUSTAINABILITY165.CORPORATE GOVERNANCE276.GRI CONTENT INDEX347.ADDENDIX																																
7.APPENDIX41	Sana Pharmn Medical has reported the information cited in this GRI content index for the period 2022 with reference to GRI 1 Foundation 2021	Comment									Change in main owner to follow up business	Change from M&A focus to organic growth										Policy reading is mandatory for all employees, this info is found there	Performed through management review renarding BoD preformance				Risk systems raison consulting helped out with policies building		PSCI			
	Sana Pharr Sans Rharr his GRI cou BRI 1: Four	LOCATION	4 4	4,5	4 4	5	23	24	23 8 15	10-12	15 42 5	5 9- 21- 26	21- 26	27-31	29	21-22 29	29	29-30		29 ND	29	29	32	6, 23-32	28 23 26 28	31.3		30 31 32	22, 22	21, 22	21, 22	21
			2-1 Organizational details 2-1-a legal name 2-1-b nature of ownership	and legal form 2-1-c location of its headquarters	2-1-d s countries of operation 2-2 Entities included in the organization's sustainability	reporting 2-2-a list of all entities included in its sustainability reporting;	2-3 Reporting period, frequency and contact point	2-4 Restatements of information	2-5 External assurance 2-6 Activities, value chain and other business	2-6 a market	2-6-b Products 2-6-b Supply chain 2-6 c: Business relations	2-6 D: Business changes 2-7 Employees	2-8 Workers who are not employees	2-10 Nomination and	selection of the highest governance body	2-10 b: Stakholders 2-11 Chair of the highest governance body	2-12 Role of the highest governance body in overseeing the	management of impacts 2-13 Delegation of responsibility for managing	impacts 2-14 Role of the highest	governance body in sustainability reporting 2-15 Conflicts of interest	2-16 Communication of critical concerns	2-17 Collective knowledge of the highest governance body	2-18 Evaluation of the performance of the highest	2-22 Statement on sustainable development	2-24 Embedding policy	commitments 2-25 Processes to remediate negative impacts	2-26 Mechanisms for	seeking advice and rasing concerns 2-27 Compliance with laws		associations 2-29 a stakholders	2-29 a i-iii stakholder engagement and materiality analysis	2-30 Collective bargaining agreements
	GRI content index Statement of use GRI 1 used Annicable GRI Sector Standard(S	GRI STANDARD/ OTHER SOURCE			GRI 2: General Disclosures 2021																											

C SANAPHARMA MEDICAL

		ENT INDEX	RMA MEDICAL3 ITUATION10 PORTFOLIO13 BILITY16 TE GOVERNANCE27
GRI content index statement of use	Sana Pha	mn Medical has reported the information cited in	
GRI 1 used Applicable GRI Sector Standard(s)	this GRI co GRI 1: Fou Universal 3	this GRI content index for the period 2022 with reference to GRI 1: Foundation 2021 Universal Standards	
_	LOCATION	1 Comment	
3-1 Process to determine material topics 3-21 ist of material topics	22, 32		
3-3 Management of material topics	22, 32	Will be part of the total managemnt system	
201-1 Direct economic value generated and distributed	7, 30, 32	Yearly P&L presnted to the BoD, and approved	
201-2 Financial implications and other risks and opportunities due to climate	23, 24	Analysis performed when riske assessment of the environmental policy was performed	
change 201-3 Defined benefit plan obligations and other retirement plans 201-4 Financial assistance received from government	26 30	Found in Employee Handbook	
3-3 Management of material topics	32		
202-1 Ratios of standard entry level wage by gender compared to local minimum wage 202-2 Proportion of senior management hired from the	21, 26 9	Senior excecutive from all countries	
local community Indirect economic impacts			
3-3 Management of			
material topics 203-1 Infrastructure investments and services supported 203-2 Significant indirect	32 Not performed Not		
_			
3-3 Management of material topics	32		
204-1 Proportion of spending on local suppliers	52		
3-3 Management of material topics 205-1 Operations assessed for risks related	32 31, 32	Negative impact analysed by Business Integrity Policy (KOL/Partners) risk assessment	
to corruption 205-2 Communication and training about anti- corruption policies and	29, 31	Communication poliy risk analysis has been performed, and training procedure followed (all policies and CoC mandatory for all employees)	
205-3 Confirmed incidents of corruption and actions taken	Non reported		
Anti-competitive behavior GRI 3: Material 3-3 Management of Topics 2021 material topics	32		
206-1 Legal actions for anti- competitive behavior, anti- trust, and monopoly	Non		

			7.APPENDIX41	1.SANA PHARMA MEDICAL3 2.MARKET SITUATION10 3.PRODUCT PORTFOLIO13 4.SUSTAINABILITY16 5.CORPORATE GOVERNANCE27 6.GRI CONTENT INDEX34	CONTENTS
GRI conter	content index				6. GRI II
Statement of use GRI 1 used Applicable GRI Sect	or Standard(s)	Sana Pharn this GRI col GRI 1: Four Universal S	Sana Pharmn Medical has reported the information cited in this GRI content index for the period 2022 with reference to GRI 1: Foundation 2021 Universal Standards		NDEX
GRI STANDARD/ OTHER SOURCE	DISCLOSURE	LOCATION	Comment		
Тах					
3: Material ics 2021	3-3 Management of material topics	32			
	207-1 Approach to tax 207-2 Tax governance, control, and risk	30 30, 32	All tax laws in every country followed, aduited year External audit yearly		
GRI 207: Tax 2019	207-3 Stakeholder engagement and management of concems	30	Yerly reported to BoD and owners		
	retated to tax 207-4 Country-by-country reporting	Yes	Country-by-country and consolidated		
GRI 3: Material Topics 2021	3-3 Management of material topics	32			
	301-1 Materials used by weight or volume				
GRI 301: Materials 2016	301-2 Recycled input materials used	Yes	Has taken away plastic around products		
	301-3 Reclaimed products and their packaging materials	Na			
GRI 3: Material Topics 2021	3-3 Management of material topics 302-1 Energy consumption h within the organization	32 Not measured			
	302-2 Energy consumption outside of the organization	Not measured			
GRI 302: Energy 2016	302-3 Energy intensity	Not measured			
	302-4 Reduction of energy N consumption E 302-5 Reductions in energy N requirements of products p and services	Not performed Not performed	We are non manufacturing products our selves		
Water and effluents GRI 3: Material Tonice 2021	3-3 Management of material tonics	32			
	303-1 Interactions with water as a shared resource	Na			SAN
	303-2 Management of water discharge-related impacts	Na			A PHA
GKI 303: Water and Effluents 2018	303-3 Water withdrawal	Na			RMA
	303-4 Water discharge 303-5 Water consumption	Na			ME
Diaditeenine	203-0 Water CONSUMPTION	Na			DICAL
BIOUIVEISILY GRI 3: Material Topics 2021	3-3 Management of material topics	32			SUST
	304-1 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside biodiversity value outside	AN			AINABILITY
GRI 304: Biodiversity 2016	304-2 Significant impacts of activities, products and services on biodiversity	NA			' REPC
`	304-3 Habitats protected or restored	NA			DRT 2
	304-4 IUCN Red List species and national conservation list species with habitats in areas affected by operations	NA			2023

CONTENTS	6. GRI INI	DEX															S	ANA PHA	ARMA	A MEE	DICAL	SUSTAI	NAB	ILITY	REP	ORT 2023	;
 SANA PHARMA MEDICAL3 MARKET SITUATION10 PRODUCT PORTFOLIO13 SUSTAINABILITY16 CORPORATE GOVERNANCE27 G.GRI CONTENT INDEX34 APPENDIX41 		ance to		vehicles																							
	a Pharmn Medical has reported the information c	this GRI content index for the period 2022 with reference to GRI 1: Foundation 2021 Universal Standards	LOCATION	32 Not owing manufacturing sites or on-site vehicles Not performed	Not performed	24 24 Not measured 25 CO2 compensation	Not measured	Not measured	-	32	23 No significant impact	Not needed	Not measured	Q	23 scrapping		Yes	Non	-	32	21	Non	Non		32	2	
	GRI content index Statement of use Sana	ector Standard(s)	GRI STANDARD/ DISCLOSURE LOCA OTHER SOURCE	GRI 3: Material 3-3 Management of 3 Topics 2021 material topics 3 05-1 Direct (Scope 1) N GHG emissions Perfo	305-2 Energy indirect N (Scope 2) GHG emissions perio	305-3 Other indirect (Scope 2 3) GHG emissions 2) GHC emissions 305-4 GHG emissions N 2016 305-5 Reduction of GHG 2056 2	300 Section 2010 S	305-7 Nitrogen oxides (NOx), sulfur oxides (SOx), N and other significant air meas emissions		GRI 3: Material 3-3 Management of 3 Topics 2021 material topics 3		306-2 Management of significant waste-related impacts		Ę	306-5 Waste directed to 2 disposal Sumption environmental assessment	3-3 Management of	308-1 New suppliers that were screened using	Assessment 2016 environmental cinetral Assessment 2016 environmental impacts in Ne the supply chain and actions taken		GKI 3: Material 3-3 Management of 3-3 Management of 3 Topics 2021 material topics 3 401-1 New employee hires		GRI 401: tull-time employees that are tull-time employees that are or provided to temporary Nk or part-time employees	401-3 Parental leave No	Labor/management relations	-3 Management of naterial topics	GRI 402: 402-1 Minimum notice Labor/Management periods regarding 2 Relations 2016 operational changes	

			 1.SANA PHARMA MEDICAL3 2.MARKET SITUATION10 3.PRODUCT PORTFOLIO13 4.SUSTAINABILITY16 5.CORPORATE GOVERNANCE27 6.GRI CONTENT INDEX	CONTENTS
GRI content index	nt index			6. GRI I
Statement of use GRI 1 used		Sana Pharr this GRI co GRI 1: Four	Sana Pharmn Medical has reported the information cited in this GRI content index for the period 2022 with reference to GRI 1: Foundation 2021	NDEX
Applicable GRI Sect	s)	Universal S	tandards	
GRI STANDARD/ OTHER SOURCE	DISCLOSURE	LOCATION	Comment	
Occupational health GRI 3: Material	and safety 3-3 Management of	32		
1 opics 2021	1 optcs 2021 minaterial topics 403-1 Occupational health and safety management			
	system 403-2 Hazard identification, risk assessment, and incident investigation	31	Exsist, but nothing found or reported	
	403-3 Occupational health services	No		
	403-4 Worker participation, consultation, and communication on occupational health and	31	All employees trained on this according to Training SOP	
GRI 403: Occupational Health and Safetv	403-5 Worker training on occupational health and safety	31	All employees trained according to Training SOP	
2018	403-6 Promotion of worker health	20	Main focus	
	403-The Prevention and 403-The Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	31	Yes, according to our risk management	
	403-8 Workers covered by an occupational health and safety management system	31		
	403-9 Work-related injuries	0		
Training and adjunct	403-10 Work-related ill health	0		
I raining and educat GRI 3: Material Topics 2021	3-3 Management of material topics	32		
	404-1 Average hours of training per year per	31, 32	Regularly and yearly training	
GRI 404: Training and Education 2016	employee 404-2 Programs for upgrading employee skills and transition assistance b programs	21, 26	All employees have yearly interview, and follow- ups program	
	404-3 Percentage of employees receiving regular performance and career development reviews	26, 32	100 %	S
Ulversity and equal GRI 3: Material Topics 2021	opportunity 3-3 Management of material topics	32		ANA
/ersity	405-1 Diversity of governance bodies and employees	26, 32		PHARI
and Equal Opportunity 2016	405-2 Ratio of basic salary and remuneration of women to men	Not measured		MA MI
Non-discrimination GRI 3: Material Tonice 2024	3-3 Management of material tonics	32		EDICA
016	406-1 Incidents of discrimination and corrective actions taken	0	0	L SUST
Freedom of associat GRI 3: Material	ttion and collective bargaini 3-3 Management of	bu		AIN
Topics 2021 GRI 407: Freedom	material topics 407-1 Operations and	32		ABILI
of Association and Collective Bargaining 2016	suppliers in which the right to freedom of association and collective bargaining may be at risk	Non		ITY REP
				ORT 20

CONTENTS	6. GRI IN	DEX																	SANA	A PHAI	RMA M	EDICAL SU	JSTAINABILITY REPORT 2	023
 SANA PHARMA MEDICAL3 MARKET SITUATION10 PRODUCT PORTFOLIO13 SUSTAINABILITY16 CORPORATE GOVERNANCE27 G.GRI CONTENT INDEX34 7.APPENDIX41 												_	I									1	1	
	i hodina dha indrind tha indrimation nited i	this Garant manufactor has reported the monitation used in this GRI 1: Foundation 2021 Universal Standards	ION Comment										ω			1. CoC sent to supplier					Yes, important			
		nis GF CEN 11: CEN 11: Drivers	DISCLOSURE	3-3 Management of 32 material topics	408-1 Operations and suppliers at significant risk Non for incidents of child labor	y labor 3-3 Management of 32 material topics	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	3-3 Management of 32 material topics	410-1 Security personnel trained in human rights NA policies or procedures	s peoples 3-3 Management of 32 material topics	411-1 Incidents of violations involving rights of indigenous peoples	3-3 Management of 32	N N	413-2 Operations with significant actual and potential negative impacts on local communities	ssment 3-3 Management of 32	ſ	criteria 414-2 Negative social impacts in the supply chain and actions taken	3-3 Management of 32	415-1 Political contributions Non	I safety 3-3 Management of 32 material topics	416-1 Assessment of the health and safety impacts of product and service	categories 416-2 Incidents of non- compliance concerning the health and safety impacts of products and services		
	GRI content index	GRI 1 used Applicable GRI Secto		Child labor GRI 3: Material Topics 2021	GRI 408: Child Labor 2016	Forced or compulsor GRI 3: Material Topics 2021	GRI 409: Forced or Compulsory Labor 2016	Security practices GRI 3: Material T opics 2021	>	Rights of indigenous GRI 3: Material Topics 2021	GRI 411: Rights of Indigenous Peoples 2016	Local communities GRI 3: Material Toxics 2024	GRI 413: Local	9	Supplier social asses GRI 3: Material		La la			Customer health and GRI 3: Material Topics 2021	GRI 416: Customer	Health and Safety 2016		

CONTENTS	6. GRI INDEX									
1.SANA PHARMA MEDICAL32.MARKET SITUATION103.PRODUCT PORTFOLIO134.SUSTAINABILITY165.CORPORATE GOVERNANCE276.GRI CONTENT INDEX347.APPENDIX41										
7.APPENDIA41	Sana Pharmn Medical has reported the information cited in this GRI content index for the period 2022 with reference to GRI 1: Foundation 2021 Universal Standards	Comment	Followed all laws and legislations. followed up throu	3 Summarized in Management Review for 2023,	as decribed page 32	2- Summarized in Management Review for 2023, as decribed page 32			O	
	Sana Pharm this GRI con GRI 1: Foun	LOCATION	32	, Kes	33	8		32	32	
		DISCLOSURE	3-3 Management of material topics 417-1 Requirements for	product and service information and labeling 417-2 Incidents of non-	compliance concerning product and service information and labeling	417-3 Incidents of non- compliance concerning marketing communications		3-3 Management of material topics	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	
	GRI content index Statement of use GRI 1 used Applicable GRI Sector Standard(s)	GRI STANDARD/ OTHER SOURCE	GRI 3: Material Topics 2021		GRI 417: Marketing and Labeling 2016		Customer privacy		GRI 418: Customer Privacy 2016	

SANAPHARMA MEDICAL

CONTENTS	7. APPENDIX	SANA PHARMA MEDICAL SUSTAINABILITY REPORT 2023
1.SANA PHARMA MEDICAL3		
2.MARKET SITUATION10		
3.PRODUCT PORTFOLIO13		
4.SUSTAINABILITY16		
5.CORPORATE GOVERNANCE27		
6.GRI CONTENT INDEX34		
7.APPENDIX41		

7. Appendix

6. GRI INDEX

1.S/	NA PHA	RMA M	EDICAL	3
2.M	ARKET S	ITUATIC	DN	10
3.PF	RODUCT	PORTFO	DLIO	13
4.Sl	JSTAINA	BILITY		16
5.C(DRPORA	TE GOV	ERNANCE	2
6.G	RI CONTE	ENT IND	EX	3
7.AI	PPENDIX			41

Excellent Supply Chain & Logistics competence

Constantly optimizing the Supply & Logistics value chain by:

- Enhancing efficiency
- Elevating quality standards
- Facilitating adaptability and flexibility
- Implementing cost reduction strategies
- Constantly refining logistics workflows and enhancements
- Implementing sustainability initiatives aimed at reducing the environmental impact of product packaging by transitioning away from plastic materials.

Performance

- Improving data management systems for product master data and supplier information to enhance communication and coordination between various stages of production and distribution, both upstream and downstream.
- Implanting robust capacity and demand planning procedures to enhance efficiency in process-driven supply chain and logistics operations.
- Developing integrated logistics solutions to foster real-time communication with suppliers and customers, enabling SMP to optimize supply chain and logistics operations effectively

Additional Information:

- · Perform accurate demand forecasting to proactively respond to market changes swiftly
- Develop a responsive and flexible supply chain with integrated solutions for precise planning
- Align product development with supply and manufacturing operations for seamless integration
- Promote green initiatives within the supply chain to bolster the company's reputation and sustainability efforts
- Ensure a consistent supply of products through reliable prediction mechanisms

